Human Genome Epidemiology Literature Finder
Records 1 - 27 (of 27 Records) |
Query Trace: CES2[original query] |
---|
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Aug 9 (9): 3246-53. Mathijssen Ron H J, Marsh Sharon, Karlsson Mats O, Xie Rujia, Baker Sharyn D, Verweij Jaap, Sparreboom Alex, McLeod Howard |
Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 2004 Oct 84 (4): 661-8. Marsh Sharon, Xiao Ming, Yu Jinsheng, Ahluwalia Ranjeet, Minton Matthew, Freimuth Robert R, Kwok Pui-Yan, McLeod Howard |
Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics 2004 Sep 14 (9): 595-605. Wu Michael H, Chen Peixian, Wu Xiaolin, Liu Wanqing, Strom Stephen, Das Soma, Cook Edwin H, Rosner Gary L, Dolan M Eile |
Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug metabolism and disposition: the biological fate of chemicals 2007 Oct 35 (10): 1865-72. Kim Su-Ryang, Sai Kimie, Tanaka-Kagawa Toshiko, Jinno Hideto, Ozawa Shogo, Kaniwa Nahoko, Saito Yoshiro, Akasawa Akira, Matsumoto Kenji, Saito Hirohisa, Kamatani Naoyuki, Shirao Kuniaki, Yamamoto Noboru, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Saijo Nagahiro, Sawada Jun-ic |
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer chemotherapy and pharmacology 2008 Mar 61 (3): 481-8. Bellott Ricardo, Le Morvan Valérie, Charasson Virginie, Laurand Armelle, Colotte Marthe, Zanger Ulrich M, Klein Kathrin, Smith Denis, Bonnet Jacques, Robert Jacqu |
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British journal of cancer 2008 Oct 99 (8): 1239-45. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M, Laurand A, Poirier A-L, Morel A, Chatelut E, Robert J, Gamelin |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Current drug metabolism 2008 May 9 (4): 336-43. Ribelles N, López-Siles J, Sánchez A, González E, Sánchez M J, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba |
Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Xenobiotica; the fate of foreign compounds in biological systems 2009 May 39 (5): 407-14. Fujiyama N, Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Habuchi T, Suzuki |
Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. The pharmacogenomics journal 2010 Dec 10 (6): 524-36. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook V J, Fitzgerald J M, Elwood K, Marra F, Brooks-Wilson |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Apr 17 (7): 2006-13. Caronia Daniela, Martin Miguel, Sastre Javier, de la Torre Julio, García-Sáenz José Angel, Alonso Maria R, Moreno Leticia T, Pita Guillermo, Díaz-Rubio Eduardo, Benítez Javier, González-Neira An |
Relationship between CES2 genetic variations and rifampicin metabolism. The Journal of antimicrobial chemotherapy 2013 Jun 68 (6): 1281-4. Song Sang Hoon, Chang Ho Eun, Jun Sun Hee, Park Kyoung Un, Lee Jae Ho, Lee Eun-Mi, Song Young-Han, Song Jungh |
Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochemical pharmacology 2016 Nov 119 76-84. Shi Jian, Wang Xinwen, Nguyen Jenny-Hoa, Bleske Barry E, Liang Yan, Liu Li, Zhu Hao-J |
The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer treatment reviews 2016 Nov 50 9-22. Lam S W, Guchelaar H J, Boven |
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaar Henk-Jan, Boven Ep |
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Frontiers in pharmacology 2017 8 347. Claudio-Campos Karla, Labastida Aurora, Ramos Alga, Gaedigk Andrea, Renta-Torres Jessicca, Padilla Dariana, Rivera-Miranda Giselle, Scott Stuart A, Ruaño Gualberto, Cadilla Carmen L, Duconge-Soler Jor |
Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. Antimicrobial agents and chemotherapy 2017 Dec . Dompreh Albert, Tang Xiaoli, Zhou Jianlin, Yang Hongmei, Topletz Ariel, Adu Ahwireng Eugene, Antwi Sampson, Enimil Antony, Langaee Taimour, Peloquin Charles A, Court Michael H, Kwara Awewu |
Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil. Mutation research. Genetic toxicology and environmental mutagenesis 2018 Dec 836 (Pt B): 97-102. Cilião Heloísa Lizotti, Camargo-Godoy Rossana Batista Oliveira, Souza Marilesia Ferreira de, Zanuto Amanda, Delfino Vinicius Daher Alvares, Cólus Ilce Mara de Syll |
Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients. Antibiotics (Basel, Switzerland) 2020 6 9 (6): . Thomas Levin, Sekhar Miraj Sonal, Surulivelrajan Mallayasamy, Varma Muralidhar, Sanju Chidananda S V, Rao Mahad |
Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. The Journal of antimicrobial chemotherapy 2020 Dec . Weiner Marc, Gelfond Jon, Johnson-Pais Teresa L, Engle Melissa, Johnson John L, Whitworth William C, Bliven-Sizemore Erin, Nsubuga Pheona, Dorman Susan E, Savic Rada, |
Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment. Toxicology letters 2021 7 350 162-170. Di Consiglio E, Darney K, Buratti F M, Turco L, Vichi S, Testai E, Lautz L S, Dorne J L C |
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. British journal of clinical pharmacology 2021 Apr . Ramirez Jacqueline, House Larry K, Ratain Mark |
Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach. Frontiers in pharmacology 2021 1 11 591854. Liu Shuaibing, Wang Ziteng, Tian Xin, Cai Weim |
Nongenetic and genetic predictors of haemodynamic instability induced by propofol and opioids: A retrospective clinical study. British journal of clinical pharmacology 2022 Aug . Gu Qing-Ling, Xue Fa-Ling, Zheng Zhuo-Ling, Wang Hai-Ni, Guan Yan-Ping, Wen Yong-Zi, Ye Fang, Huang Min, Huang Wen-Qi, Wang Zhong-Xing, Li Jia- |
Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review. Pharmacogenomics and personalized medicine 2022 15 561-571. Sileshi Tesemma, Mekonen Gosaye, Makonnen Eyasu, Aklillu Ele |
Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants. International journal of molecular sciences 2023 9 24 (17): . Lanuza A P Faccioli, Zeliha Cetin, Zehra N Kocas-Kilicarslan, Kimberly Ortiz, Yiyue Sun, Zhiping Hu, Takeshi Kurihara, Edgar N Tafaleng, Rodrigo M Florentino, Zi Wang, Mengying Xia, Mark T Miedel, D Lansing Taylor, Jaideep Behari, Alina Ostrowska, Robert Constantine, Albert Li, Alejandro Soto-Gutierr |
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 1 159 114232. de With Mirjam, van Doorn Leni, Maasland Demi C, Mulder Tessa A M, Oomen-de Hoop Esther, Mostert Bianca, Homs Marjolein Y V, El Bouazzaoui Samira, Mathijssen Ron H J, van Schaik Ron H N, Bins Sand |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: